Global Pleurisy Market Size By Type (Thoracentesis, Video-Assisted Thoracic Surgery), By Application (Hospital, Clinics), By Region, And Segment Forecasts, 2023 to 2032

lobal Pleurisy Market Report Description

The Global Pleurisy Market was valued at USD 1.8 billion in 2023 and is projected to reach USD 3.2 billion by 2031, growing at a CAGR of 7.1% during the forecast period (2023–2031).

The market growth is driven by the rising prevalence of respiratory disorders, the increasing elderly population, advancements in diagnostic imaging and minimally invasive treatments, and greater awareness of pleural diseases. Pleurisy, an inflammation of the pleura surrounding the lungs, is often associated with infections, lung cancer, autoimmune diseases, and post-surgical complications.

The demand for early diagnosis, improved therapeutic options, and advanced imaging techniques such as ultrasound and CT scans is boosting the adoption of effective management strategies for pleurisy worldwide.

Drivers

Rising Prevalence of Respiratory Diseases

The increasing incidence of pneumonia, tuberculosis, lung cancer, and chronic obstructive pulmonary disease (COPD) has significantly contributed to pleurisy cases. This trend is especially pronounced in developing nations with high infection rates.

Advancements in Diagnostic and Therapeutic Technologies

The introduction of advanced imaging techniques, thoracoscopic procedures, and targeted anti-inflammatory therapies has improved the detection and management of pleurisy.

Growing Awareness & Healthcare Access

Government initiatives and health campaigns are raising awareness about early symptoms of pleural inflammation, leading to faster diagnosis and improved treatment outcomes.

Restraints

High Cost of Advanced Imaging and Treatment

The cost of diagnostic imaging and surgical interventions remains high, particularly in low-income regions, hindering market accessibility.

Lack of Skilled Professionals

The effective diagnosis and treatment of pleurisy require pulmonologists and thoracic surgeons, which are limited in developing countries.

Opportunities

Emerging Markets with Untapped Potential

Expanding healthcare infrastructure in Asia-Pacific, Latin America, and Africa presents significant opportunities for market growth.

Development of Targeted Therapies

Ongoing research in anti-inflammatory and immune-modulating drugs opens doors for more effective pleurisy treatment options.

Telemedicine & Remote Diagnostics

Integration of telemedicine and AI-based imaging analysis can accelerate diagnosis and improve healthcare delivery in remote areas.

Market by System Type Insights

Diagnostic Imaging Systems (Ultrasound & CT Scans) held the largest share in 2023 due to their critical role in detecting pleural effusions and inflammation.

Thoracoscopic and Minimally Invasive Surgical Equipment is expected to grow at the fastest pace, driven by increasing demand for less invasive treatment options.

Market by End-Use Insights

Hospitals & Specialty Clinics accounted for the largest market share in 2023 as they provide comprehensive diagnostic and therapeutic care.

Ambulatory Surgical Centers are expected to grow rapidly due to the increasing preference for outpatient thoracoscopic procedures.

Market by Regional Insights

North America dominated the market in 2023, driven by advanced healthcare infrastructure, high prevalence of lung cancer and infections, and the availability of modern diagnostic tools.

Asia-Pacific is projected to witness the highest growth during the forecast period due to the rising burden of respiratory diseases, expanding healthcare access, and increasing awareness.

Europe remains a significant market owing to the high adoption of advanced diagnostic imaging and well-established pulmonology practices.

Competitive Scenario

Key players operating in the global pleurisy market include:

Pfizer Inc.

Novartis AG

GlaxoSmithKline plc

Roche Holding AG

AstraZeneca plc

Siemens Healthineers

Medtronic plc

GE Healthcare

These companies are focusing on drug innovations, advanced diagnostic imaging technologies, and partnerships with healthcare providers to strengthen their market presence.

Recent developments include:

2023: Roche launched an advanced diagnostic biomarker assay for early detection of pleural inflammation.

2024: Siemens Healthineers introduced an AI-enabled imaging software that enhances pleural effusion analysis.

2025: Pfizer announced a clinical trial for a novel anti-inflammatory therapy targeting pleural diseases.

Scope of Work – Global Pleurisy Market

Key Market Developments

July 2023: Siemens Healthineers introduced AI-driven pleural effusion imaging analysis tools for faster diagnosis.

February 2024: Pfizer announced Phase III trials of a novel anti-inflammatory drug for pleural inflammation.

May 2024: Medtronic partnered with hospitals in Asia-Pacific to expand minimally invasive thoracoscopic procedures.

FAQs

What is the current market size of the Global Pleurisy Market?

The market size was valued at USD 1.8 billion in 2023.

What is the major growth driver of the Global Pleurisy Market?

The rising prevalence of respiratory diseases and advancements in diagnostic imaging technologies are key growth drivers.

Which is the largest region during the forecast period in the Global Pleurisy Market?

North America is expected to maintain the largest market share due to advanced healthcare infrastructure.

Which segment accounted for the largest market share in the Global Pleurisy Market?

Hospitals & Specialty Clinics accounted for the largest share in 2023.

Who are the key market players in the Global Pleurisy Market?

Key players include Pfizer, Novartis, Roche, AstraZeneca, Siemens Healthineers, and Medtronic.

Would you like me to also create a visual one-page summary (infographic style) of this report for presentation or marketing purposes?